The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

Venclexta + azacitidine receive breakthrough therapy designation from FDA for myelodysplastic syndromes

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Venclexta (venetoclax) in combination with azacitidine was granted Breakthrough Therapy Designation from FDA for the treatment of adult patients with previously untreated intermediate, high- and very high-risk myelodysplastic syndromes based on the revised International Prognostic Scoring System. 

This designation was granted based on interim results from the phase Ib M15-531 study investigating Venclexta plus azacitidine in people with previously untreated, higher-risk MDS.

This is the 38th BTD for Genentech’s portfolio of medicines, and the 11th designation for its hematology portfolio.

Venclexta is being developed by AbbVie and Genentech, a member of the Roche Group.

Table of Contents

YOU MAY BE INTERESTED IN

Sponsored

Harnessing innovation: The next frontier in surgical oncology

The field of surgical oncology has undergone transformative advancements over the last decade. From refining minimally invasive techniques to leveraging immunotherapy and viral oncolytics, our collective goal remains the same: improving patient outcomes while reducing treatment burden. At City of Hope, we have prioritized accelerating the translation of laboratory discoveries into clinical applications, and nowhere is this more evident than in our work with oncolytic viruses, remote surgery, and the integration of AI in surgical decision-making.
By Yuman Fong
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account